Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBL 137

Next Previous
Drug Profile

CBL 137

Alternative Names: CBL-0137; CBLC-137; Curaxin CBL0137; SP-537

Latest Information Update: 24 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cleveland BioLabs
  • Developer Incuron; National Cancer Institute (USA); Roswell Park Cancer Institute; Stamford Pharmaceuticals; Statera BioPharma
  • Class Antineoplastics; Carbazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse intrinsic pontine glioma; Lymphoma; Osteosarcoma; Solid tumours
  • Preclinical Pancreatic cancer
  • No development reported Haematological malignancies; Malignant melanoma; Neuroblastoma; Sarcoma

Most Recent Events

  • 24 Sep 2025 Preclinical trials in Pancreatic cancer in USA (Parenteral), prior to September 2025 (Stamford Pharmaceuticals pipeline, September 2025)
  • 30 May 2025 Efficacy and adverse events data from phase I/II clinical trials in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 25 Apr 2025 Pharmacodynamics data from preclinical studies in Medulloblastoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top